Report cover image

Global Direct Acting Antivirals Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 191 Pages
SKU # APRC20277107

Description

Summary

According to APO Research, The global Direct Acting Antivirals market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Direct Acting Antivirals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Direct Acting Antivirals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Direct Acting Antivirals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Direct Acting Antivirals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Direct Acting Antivirals include AbbVie, Asegua Therapeutics, Bristol Myers Squibb, Gilead Sciences, Merck, Ascletis Pharma, Cosunter pharmaceutical, Kawin Technology and Sanhome Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Direct Acting Antivirals, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Direct Acting Antivirals, also provides the sales of main regions and countries. Of the upcoming market potential for Direct Acting Antivirals, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Direct Acting Antivirals sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Direct Acting Antivirals market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Direct Acting Antivirals sales, projected growth trends, production technology, application and end-user industry.

Direct Acting Antivirals Segment by Company

AbbVie
Asegua Therapeutics
Bristol Myers Squibb
Gilead Sciences
Merck
Ascletis Pharma
Cosunter pharmaceutical
Kawin Technology
Sanhome Pharmaceutical
Beijing Sihuan Pharmaceutical
YiChang HEC ChangJiang Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Direct Acting Antivirals Segment by Type

Pangenotypic
Genotype-Specific
Direct Acting Antivirals Segment by Application

Hospital and Clinic
Pharmacy
Other
Direct Acting Antivirals Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Direct Acting Antivirals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Direct Acting Antivirals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Direct Acting Antivirals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Direct Acting Antivirals market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Direct Acting Antivirals manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Direct Acting Antivirals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Direct Acting Antivirals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

191 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Direct Acting Antivirals Market Size, 2020 VS 2024 VS 2031
1.3 Global Direct Acting Antivirals Market Size Estimates and Forecasts (2020-2031)
1.4 Global Direct Acting Antivirals Sales Estimates and Forecasts (2020-2031)
1.5 Global Direct Acting Antivirals Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Direct Acting Antivirals Market Dynamics
2.1 Direct Acting Antivirals Industry Trends
2.2 Direct Acting Antivirals Industry Drivers
2.3 Direct Acting Antivirals Industry Opportunities and Challenges
2.4 Direct Acting Antivirals Industry Restraints
3 Direct Acting Antivirals Market by Manufacturers
3.1 Global Direct Acting Antivirals Revenue by Manufacturers (2020-2025)
3.2 Global Direct Acting Antivirals Sales by Manufacturers (2020-2025)
3.3 Global Direct Acting Antivirals Average Sales Price by Manufacturers (2020-2025)
3.4 Global Direct Acting Antivirals Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Direct Acting Antivirals Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Direct Acting Antivirals Manufacturers, Product Type & Application
3.7 Global Direct Acting Antivirals Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Direct Acting Antivirals Market CR5 and HHI
3.8.2 Global Top 5 and 10 Direct Acting Antivirals Players Market Share by Revenue in 2024
3.8.3 2024 Direct Acting Antivirals Tier 1, Tier 2, and Tier 3
4 Direct Acting Antivirals Market by Type
4.1 Direct Acting Antivirals Type Introduction
4.1.1 Pangenotypic
4.1.2 Genotype-Specific
4.2 Global Direct Acting Antivirals Sales by Type
4.2.1 Global Direct Acting Antivirals Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Direct Acting Antivirals Sales by Type (2020-2031)
4.2.3 Global Direct Acting Antivirals Sales Market Share by Type (2020-2031)
4.3 Global Direct Acting Antivirals Revenue by Type
4.3.1 Global Direct Acting Antivirals Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Direct Acting Antivirals Revenue by Type (2020-2031)
4.3.3 Global Direct Acting Antivirals Revenue Market Share by Type (2020-2031)
5 Direct Acting Antivirals Market by Application
5.1 Direct Acting Antivirals Application Introduction
5.1.1 Hospital and Clinic
5.1.2 Pharmacy
5.1.3 Other
5.2 Global Direct Acting Antivirals Sales by Application
5.2.1 Global Direct Acting Antivirals Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Direct Acting Antivirals Sales by Application (2020-2031)
5.2.3 Global Direct Acting Antivirals Sales Market Share by Application (2020-2031)
5.3 Global Direct Acting Antivirals Revenue by Application
5.3.1 Global Direct Acting Antivirals Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Direct Acting Antivirals Revenue by Application (2020-2031)
5.3.3 Global Direct Acting Antivirals Revenue Market Share by Application (2020-2031)
6 Global Direct Acting Antivirals Sales by Region
6.1 Global Direct Acting Antivirals Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Direct Acting Antivirals Sales by Region (2020-2031)
6.2.1 Global Direct Acting Antivirals Sales by Region (2020-2025)
6.2.2 Global Direct Acting Antivirals Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Direct Acting Antivirals Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Direct Acting Antivirals Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Direct Acting Antivirals Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Direct Acting Antivirals Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Direct Acting Antivirals Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Direct Acting Antivirals Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Direct Acting Antivirals Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Direct Acting Antivirals Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Direct Acting Antivirals Revenue by Region
7.1 Global Direct Acting Antivirals Revenue by Region
7.1.1 Global Direct Acting Antivirals Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Direct Acting Antivirals Revenue by Region (2020-2025)
7.1.3 Global Direct Acting Antivirals Revenue by Region (2026-2031)
7.1.4 Global Direct Acting Antivirals Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Direct Acting Antivirals Revenue (2020-2031)
7.2.2 North America Direct Acting Antivirals Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Direct Acting Antivirals Revenue (2020-2031)
7.3.2 Europe Direct Acting Antivirals Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Direct Acting Antivirals Revenue (2020-2031)
7.4.2 Asia-Pacific Direct Acting Antivirals Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Direct Acting Antivirals Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Direct Acting Antivirals Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 AbbVie
8.1.1 AbbVie Comapny Information
8.1.2 AbbVie Business Overview
8.1.3 AbbVie Direct Acting Antivirals Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 AbbVie Direct Acting Antivirals Product Portfolio
8.1.5 AbbVie Recent Developments
8.2 Asegua Therapeutics
8.2.1 Asegua Therapeutics Comapny Information
8.2.2 Asegua Therapeutics Business Overview
8.2.3 Asegua Therapeutics Direct Acting Antivirals Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Asegua Therapeutics Direct Acting Antivirals Product Portfolio
8.2.5 Asegua Therapeutics Recent Developments
8.3 Bristol Myers Squibb
8.3.1 Bristol Myers Squibb Comapny Information
8.3.2 Bristol Myers Squibb Business Overview
8.3.3 Bristol Myers Squibb Direct Acting Antivirals Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Bristol Myers Squibb Direct Acting Antivirals Product Portfolio
8.3.5 Bristol Myers Squibb Recent Developments
8.4 Gilead Sciences
8.4.1 Gilead Sciences Comapny Information
8.4.2 Gilead Sciences Business Overview
8.4.3 Gilead Sciences Direct Acting Antivirals Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Gilead Sciences Direct Acting Antivirals Product Portfolio
8.4.5 Gilead Sciences Recent Developments
8.5 Merck
8.5.1 Merck Comapny Information
8.5.2 Merck Business Overview
8.5.3 Merck Direct Acting Antivirals Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Merck Direct Acting Antivirals Product Portfolio
8.5.5 Merck Recent Developments
8.6 Ascletis Pharma
8.6.1 Ascletis Pharma Comapny Information
8.6.2 Ascletis Pharma Business Overview
8.6.3 Ascletis Pharma Direct Acting Antivirals Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Ascletis Pharma Direct Acting Antivirals Product Portfolio
8.6.5 Ascletis Pharma Recent Developments
8.7 Cosunter pharmaceutical
8.7.1 Cosunter pharmaceutical Comapny Information
8.7.2 Cosunter pharmaceutical Business Overview
8.7.3 Cosunter pharmaceutical Direct Acting Antivirals Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Cosunter pharmaceutical Direct Acting Antivirals Product Portfolio
8.7.5 Cosunter pharmaceutical Recent Developments
8.8 Kawin Technology
8.8.1 Kawin Technology Comapny Information
8.8.2 Kawin Technology Business Overview
8.8.3 Kawin Technology Direct Acting Antivirals Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Kawin Technology Direct Acting Antivirals Product Portfolio
8.8.5 Kawin Technology Recent Developments
8.9 Sanhome Pharmaceutical
8.9.1 Sanhome Pharmaceutical Comapny Information
8.9.2 Sanhome Pharmaceutical Business Overview
8.9.3 Sanhome Pharmaceutical Direct Acting Antivirals Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Sanhome Pharmaceutical Direct Acting Antivirals Product Portfolio
8.9.5 Sanhome Pharmaceutical Recent Developments
8.10 Beijing Sihuan Pharmaceutical
8.10.1 Beijing Sihuan Pharmaceutical Comapny Information
8.10.2 Beijing Sihuan Pharmaceutical Business Overview
8.10.3 Beijing Sihuan Pharmaceutical Direct Acting Antivirals Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Beijing Sihuan Pharmaceutical Direct Acting Antivirals Product Portfolio
8.10.5 Beijing Sihuan Pharmaceutical Recent Developments
8.11 YiChang HEC ChangJiang Pharmaceutical
8.11.1 YiChang HEC ChangJiang Pharmaceutical Comapny Information
8.11.2 YiChang HEC ChangJiang Pharmaceutical Business Overview
8.11.3 YiChang HEC ChangJiang Pharmaceutical Direct Acting Antivirals Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 YiChang HEC ChangJiang Pharmaceutical Direct Acting Antivirals Product Portfolio
8.11.5 YiChang HEC ChangJiang Pharmaceutical Recent Developments
8.12 Chia Tai Tianqing Pharmaceutical
8.12.1 Chia Tai Tianqing Pharmaceutical Comapny Information
8.12.2 Chia Tai Tianqing Pharmaceutical Business Overview
8.12.3 Chia Tai Tianqing Pharmaceutical Direct Acting Antivirals Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 Chia Tai Tianqing Pharmaceutical Direct Acting Antivirals Product Portfolio
8.12.5 Chia Tai Tianqing Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Direct Acting Antivirals Value Chain Analysis
9.1.1 Direct Acting Antivirals Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Direct Acting Antivirals Production Mode & Process
9.2 Direct Acting Antivirals Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Direct Acting Antivirals Distributors
9.2.3 Direct Acting Antivirals Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.